171 related articles for article (PubMed ID: 10760418)
1. Primary central nervous system lymphoma in Japan: a nationwide survey.
Hayabuchi N; Shibamoto Y; Onizuka Y
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):265-72. PubMed ID: 10760418
[TBL] [Abstract][Full Text] [Related]
2. Systemic chemotherapy with vincristine, cyclophosphamide, doxorubicin and prednisolone following radiotherapy for primary central nervous system lymphoma: a phase II study.
Shibamoto Y; Sasai K; Oya N; Hiraoka M
J Neurooncol; 1999 Apr; 42(2):161-7. PubMed ID: 10421074
[TBL] [Abstract][Full Text] [Related]
3. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
4. Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.
Oguchi M; Ikeda H; Isobe K; Hirota S; Hasegawa M; Nakamura K; Sasai K; Hayabuchi N
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):161-8. PubMed ID: 10924986
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of primary central nervous system lymphoma: the role of chemotherapy].
Maeda Y; Matsumoto K; Kuriyama M; Ono Y; Kunishio K; Tamiya T; Furuta T; Ohmoto T
Gan To Kagaku Ryoho; 1997 May; 24(7):807-13. PubMed ID: 9170518
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
7. Strong correlation between imaging response and survival among patients with primary central nervous system lymphoma: a secondary analysis of RTOG studies 83-15 and 88-06.
Corn BW; Dolinskas C; Scott C; Donahue B; Schultz C; Nelson DF; Fisher B
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):299-303. PubMed ID: 10802352
[TBL] [Abstract][Full Text] [Related]
8. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL).
Brada M; Hjiyiannakis D; Hines F; Traish D; Ashley S
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1157-62. PubMed ID: 9539572
[TBL] [Abstract][Full Text] [Related]
9. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy?
O'Neill BP; O'Fallon JR; Earle JD; Colgan JP; Brown LD; Krigel RL
Int J Radiat Oncol Biol Phys; 1995 Oct; 33(3):663-73. PubMed ID: 7558957
[TBL] [Abstract][Full Text] [Related]
10. Results of primary central nervous system lymphoma treated by radiation and chemotherapy: retrospective analysis of twelve institutions in the Tokai District of Japan, 1995-1999.
Kawamura T; Ishiguchi T; Shibamoto Y; Ogino H; Ishihara S; Yamada T; Katada K; Suzuki K; Suzuki H; Mimura M
Radiat Med; 2006 Jan; 24(1):9-16. PubMed ID: 16715656
[TBL] [Abstract][Full Text] [Related]
11. Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine-doxorubicin-cyclophosphamide-prednisolone chemotherapy.
Shibamoto Y; Tsutsui K; Dodo Y; Yamabe H; Shima N; Abe M
Cancer; 1990 May; 65(9):1907-12. PubMed ID: 2372761
[TBL] [Abstract][Full Text] [Related]
12. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06.
Schultz C; Scott C; Sherman W; Donahue B; Fields J; Murray K; Fisher B; Abrams R; Meis-Kindblom J
J Clin Oncol; 1996 Feb; 14(2):556-64. PubMed ID: 8636771
[TBL] [Abstract][Full Text] [Related]
13. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD).
Glass J; Shustik C; Hochberg FH; Cher L; Gruber ML
J Neurooncol; 1996 Dec; 30(3):257-65. PubMed ID: 8943101
[TBL] [Abstract][Full Text] [Related]
14. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma.
Ichikawa T; Kurozumi K; Michiue H; Ishida J; Maeda Y; Kondo E; Kawasaki A; Date I
Clin Neurol Neurosurg; 2014 Dec; 127():106-11. PubMed ID: 25459253
[TBL] [Abstract][Full Text] [Related]
15. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
17. AIDS-related central nervous system lymphomas.
Chamberlain MC; Kormanik PA
J Neurooncol; 1999 Jul; 43(3):269-76. PubMed ID: 10563433
[TBL] [Abstract][Full Text] [Related]
18. Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M).
Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ogawa M; Tominaga S; Tsugane S; Minato K
Jpn J Clin Oncol; 1988 Jun; 18(2):113-24. PubMed ID: 3379782
[TBL] [Abstract][Full Text] [Related]
19. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma.
Fisher B; Seiferheld W; Schultz C; DeAngelis L; Nelson D; Schold SC; Curran W; Mehta M
J Neurooncol; 2005 Sep; 74(2):201-5. PubMed ID: 16193393
[TBL] [Abstract][Full Text] [Related]
20. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
